Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | VEGFA | P15692 | 3/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200385 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL13561243 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL7049923 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL6286986 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL21662370 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL9231092 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL9229342 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL8506716 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL12427213 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL2195712 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0394280-B1 | ESTERS OF GLYCOSIDES AND A PROCESS FOR ENZYMATIC PREPARATION THEREOF | NOVO NORDISK AS (DK) | 1995-04-05 | — | — | EP | claimed |
| US-20210161189-A1 | MONOESTER SUGAR DERIVATIVES AS FLAVOR MODIFIERS | FIRMENICH SA (CH) | 2021-06-03 | — | — | US | disclosed |
| WO-1994012651-A1 | ENZYMATIC SYNTHESIS OF SUGAR ALCOHOL ESTERS | NOVO NORDISK A/S (DK) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161189-A1 | MONOESTER SUGAR DERIVATIVES AS FLAVOR MODIFIERS | TAS2R40, TAS2R30, TAS2R50 | TLR4 440/4885SLC2A1 187/4885DGKA 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.